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Unfortunately, the mutagenic activities of chemotherapy and
radiotherapy can provoke development of therapy-induced
malignancies in cancer survivors. Non-mutagenic anti-cancer
therapies may be less likely to trigger subsequent malignant
neoplasms. Here we present data regarding the DNA damaging and
mutagenic potential of two drugs that antagonize proteins within
the Bcl-2 family: ABT-263/Navitoclax and TW-37. Our data reveal
that concentrations of these agents that stimulated Bax/Bak-
dependent signaling provoked little DNA damage and failed to
trigger mutations in surviving cells. The data supplied in this
article is related to the research work entitled "Inhibition of Bcl-2
or IAP proteins does not provoke mutations in surviving cells" [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology
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M.M. Green et al. / Data in Brief 6 (2016) 710–714 711ow data was
acquiredClonogenicity assays, HPRT mutagenesis assays, γH2AX ﬂow cytometry
quantitationata format Normalized data
xperimental
factorsMurine embryonic ﬁbroblasts from wild type or Bax / , Bak / mice were
treated with various concentrations of ABT-263 or TW-37, prior to the assays
listed above.xperimental
featuresCells were exposed to drugs (or not) for various periods of time, then washed
and either stained with anti-γH2AX for ﬂow cytometry, seeded into normal
media to quantitate clonogenicity, or seeded into media containing 6-
thioguanine to count 6-thioguanine-resistant clones (presumably reﬂecting
mutagenesis at the HPRT locus).ata source
locationLa Trobe University, Bundoora, Australiaata accessibility Data is included within this articleValue of the data
 These data can be used to compare the mutagenic potentials of anti-cancer drugs that employ
different mechanisms of action
 Future research could deﬁne the pathways through which high concentrations of some BH3-
mimetics kill cells and damage DNA
 Researchers could use this data to design animal-based experiments to evaluate the mutagenic and
oncogenic activity of Bcl-2 antagonists in vivo1. Data
Embryonic ﬁbroblasts derived fromwildtype or Bax/Bak-deﬁcient mice were treated with ABT-263
(Fig. 1) or TW-37 (Fig. 2), or incubated in normal medium. We measured the impact of these treat-
ments on survival, DNA damage and mutagenicity at the HPRT locus.2. Experimental design, materials and methods
2.1. Cell lines and materials
SV-40 transformed Mouse Embryonic Fibroblasts (MEF) were kindly provided by Anissa Jabbour
and Paul Ekert [2] and were cultured in DMEM high glucose (Invitrogen; Carlsbad, California, USA)
containing 10% fetal calf serum (Invitrogen). ABT-263 and TW-37 were purchased from Selleck
Chemicals (Houston, Texas, USA). The following antibodies were used: anti-H2AX (Ser 139) clone
20E3 (Cell Signaling Technology) and goat anti-rabbit FITC (Chemicon).2.2. Cell survival assays
The toxicity of the drugs was assessed by comparing the clonogenic survival of treated and
untreated cells. Cells were incubated with drugs, then washed and seeded at various densities in 6-
well plates. After seven days, cells were stained with methylene blue (Sigma Aldrich) 1.25 g/l in 50%
methanol, incubated for 5 min and washed twice with water, then the numbers of colonies were
counted.
Fig. 1. ABT-263 kills MEF cells very inefﬁciently and fails to stimulate DNA damage or mutagenesis in surviving cells. Murine
embryonic ﬁbroblasts (MEF) fromwild type (WT) or Bax/Bak knockout (BB DKO) mice were incubated with the indicated doses
of ABT-263 for the speciﬁed periods of time. The cells were then subjected to clonogenicity assays (A), analyzed by ﬂow
cytometry to determine the proportion in which H2AX proteins were phosphorylated (γH2AX) (B) or incubated in 6-TG-
containing medium (C). The reported peak plasma concentration for patients administered ABT-263 was 3.6 mM [7]. (A–C) Error
bars indicate standard errors of the means from three independent experiments.
M.M. Green et al. / Data in Brief 6 (2016) 710–7147122.3. HPRT assay
To evaluate the ability of the drugs to provoke mutations in clonogenically-competent cells, we
quantitated the emergence of colonies in media containing 6-thioguanine (6-TG), using a previously
published method [1,3]. This purine analog is toxic to cells expressing functional hypoxanthine-guanine
phosphoribosyltransferase (HPRT) and growth of colonies in 6-TG following drug treatment usually
Fig. 2. TW-37 is non-mutagenic and high concentrations damage DNA predominantly through Bax/Bak-independent
pathways. Murine embryonic ﬁbroblasts (MEF) from wild type (WT) or Bax/Bak knockout (BB DKO) mice were incubated with
the indicated doses of TW-37 for the speciﬁed periods of time. The cells were then subjected to clonogenicity assays (A),
analyzed by ﬂow cytometry to determine the proportion in which H2AX proteins were phosphorylated (γH2AX) (B) or incu-
bated in 6-TG-containing medium (C). (A–C) Error bars indicate standard errors of the means from three independent
experiments.
M.M. Green et al. / Data in Brief 6 (2016) 710–714 713results from drug-induced loss-of-function mutations at the HPRT locus [4]. Cells were incubated with the
drug or normal media, thenwashed and incubated in normal media for eight days to allow for expression
of the HPRT mutant phenotype. Cells were then seeded at 105 cells per 150 mm dish (three dishes per
treatment) in media containing 6-thioguanine (Sigma Aldrich). Colonies were stained with methylene
blue and counted after 13 days. The number of 6-TG-resistant colonies following drug treatment was
calculated by subtracting the number of background colonies that arose in untreated samples.
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Drug-induced DNA damage was examined by measuring the proportion of cells bearing phos-
phorylated H2AX, which typically occurs in response to double-stranded DNA breaks [5]. Staining of
phosphorylated H2AX was based on a published protocol [6]. Cells were exposed to drugs then
stained using anti-phosphorylated H2AX and anti-rabbit FITC antibodies. After washing to remove
unbound antibodies, the cells were resuspended in PBS containing PI (5 mg/ml) to limit the analysis to
permeabilized intact cells (excluding cells with sub-G1 DNA content). The γH2AX signals from these
cells were analyzed using a FACS Canto (BD Biosciences).Acknowledgments
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